Mr Darren Barton BSc

Mr Darren Barton

Institute of Cancer and Genomic Sciences
D3B Trial Management Team Leader

Contact details

+44 (0)121 371 8027
+44 (0)121 371 7246
Office 10, 5th Floor
Open Plan East, Institute for Translational Medicine (ITM)
Heritage Building,
Mindelsohn Way,
Birmingham, B15 2TH

Darren Barton is the D3B Trials Team Leader at the at the Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, at the University of Birmingham.


BSC (Hons) Marine Biology, 1995


Darren Barton Graduated with a BSC (Hons) Marine Biology from Bangor University (North Wales: 1992-1995), After working in pre-clinical toxicology in animal models (both standard toxicology and reproductive and behavioural toxicology in the role of;  Histologist, Necropsy/pathology specialist and Study supervisor for approximately 5 years.

Darren Joined CRCTU in July 2002 as a trial administrator, working in the field of urology (Prostate cancer and Bladder cancer). In 2005 Darren was promoted to Trial coordinator and his first investigator-led study was entitled: TRAPEZE a phase II/III randomised study combine strontium-89, Zoledronic acid and docetaxel chemotherapy in patients with advanced metastatic prostate cancer involving the bone.

Darren has subsequently coordinated (National coordinator and Local coordinator) a number of  academic Phase I,II clinical trials involving medical devices, Investigational Medicinal Products (IMPs), Advanced therapy investigational products (ATIMPs) In the field of liver disease. The majority of which were after he was promoted to senior trial coordinator (2009) and he was one of the first appointees to the new NIHR Liver Biomedical research unit Founded in August 2009.

Darren was responsible along with other senior member of the team for managing a wide portfolio of industry sponsored liver trials (HCV, Auto-immune disease, liver transplantation, NASH) as well as the coordinator for Multiple investigator –led academic/industry collaboration Phase I/II trials in Liver cirrhosis, Non-alcoholic fatty-liver disease, and Hepatitis C reinfection (post-transplant- prevention). This studies involved IMPs, Biological therapy and medical devices. He has worked closely with industry and various clinical teams at the Queen Elizabeth hospital and has run trials on behalf of the university of Birmingham (sponsor) and local site.

In 2016 Darren was appointed a D3B Trials team leader and currently leads the new D3B team portfolio (which includes a wide range of studies in area of trauma medicine, neurology, ophthalmology, surgery, medical devices and inflammatory diseases. D3B is a core member of the Birmingham Health partners ITM initiative.


Darren Barton has contributed to the design, set-up and/or management of the following Trials since joining the Liver BRU (2009): 

  • ITX5061 (Hepatitis C prevention of re-infection immediately pre to and post liver transplant)
  • LEAN (Non-alcoholic Fatty Liver disease)
  • REALISTIC (Liver Cirrhosis)
  • MERLIN (Primary Sclerosing Cholangitis)
  • VITTAL (Liver Transplant: OrganoxMetra® medical device)


Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial. Philip Noel Newsome, Richard Fox, Andrew L King, Darren Barton, Nwe-Ni Than, Joanna Moore, Christopher Corbett, Sarah Townsend, James Thomas, Kathy Guo, Diana Hull, Heather A Beard, Jacqui Thompson, Anne Atkinson, Carol Bienek, Neil McGowan, Neil Guha, John Campbell, Dan Hollyman, Deborah Stocken, Christina Yap, Stuart John Forbes. Published online November 7, 2017 

Gene expression profiling in bladder cancer identifies potential therapeutic targets. Hussain S. A., Palmer D. H., Syn W-K.,Sacco J. J., Greensmitth R. M. D., Elmetwali T., Aachi V., Lloyd B. H., Jithesh P. V., Arrand J., Barton D. Ansari J., Sibson D. R., and James N. D., International Journal of Oncology, 2017. 50(4): p. 1147-1159. 

Viability testing and transplantation of marginal livers (VITTAL) using normothermic machine perfusion: study protocol for an open-label, non-randomised, prospective, single-arm trial. Laing, R. W., Mergental, H., Yap, C., Kirkham, A., Whilku, M., Barton, D., Mirza, D. F. (2017). BMJ Open, 7(11), e017733. 

A Multicentre, Phase II, Open-Label, Randomised Controlled Trial of Repeated Autologous Infusions of Granulocyte Colony Stimulating Factor Mobilised Cd133 + Bone Marrow Stem Cells in Patients with Cirrhosis P.N. Newsome, R. Fox, A. King, N. Than, J. Moore, C. Corbett, S. Townsend, D. Barton, and others DOI: Journal of Hepatology, Vol. 64, Issue 2, S183–S184 

Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).  Andronis, L., Goranitis, I., Pirrie, S., Pope, A., Barton, D., Collins, S., Daunton, A., McLaren, D., O'Sullivan, J. M., Parker, C., Porfiri, E., Staffurth, J., Stanley, A., Wylie, J., Beesley, S., Birtle, A., Brown, J. E., Chakraborti, P., Hussain, S. A., Russell, J. M., Billingham, L. J. and James, N. D. (2016), BJU Int. doi:10.1111/bju.13549

Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both :  The TRAPEZE Randomized Clinical Trial Nicholas D. James, PhD, FRCR, FRCP; Sarah J. Pirrie, MSc; Ann M. Pope, PhD; Darren Barton, BSc; et al JAMA Oncol. 2016;2(4):493-499. doi:10.1001/jamaoncol.2015.5570

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study Matthew James Armstrong, Pies Gaunt, Guruprasad P Aithal, Darren Barton, Diana Hull, Richard Parker, Jonathan M Hazlehurst, Kathy Guo, Lean Trial Team (7 members), Philip Newsome The Lancet Volume 387 (2016) 679-690.

Effect of liraglutide on adipose insulin resistance and hepatitic de-novo lipogenesis in non-alcoholic steatohepatitits: sub-study of a phase 2, randomised placebo controlled trial  Matthew Armstrong, Diana Hull, Kathy Guo, Darren Barton, Jinglei Yu, Jeremy Tomlinson, and others  The Lancet, Vol. 387, No. 10019, p679–690 Published online: November 19, 2015 DOI:  The Lancet, Vol. 383, S21 Published in issue: February 26, 2014 

Effect of scavenger receptor BI antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation Ian A Rowe, Damien C Tully, Matthew J Armstrong, Richard Parker, Kathy Guo, Darren Barton, Gene D Morse, Charles S Venuto, Colin B Ogilvie, Ditte L Hedegaard, Jeffrey F McKelvy, Flossie Wong-Staal, Todd M Allen, Peter Balfe, Jane A McKeating and David J Mutimer. Accepted manuscript online: 5 OCT 2015 :  Liver Transplantation DOI: 10.1002/lt.24349 

REpeated AutoLogous Infusions of STem cells In Cirrhosis (REALISTIC), a multicentre, phase II, open-label, randomised controlled trial of repeated autologous infusions of granulocyte colony stimulating factor (GCSF) mobilised CD133+ bone marrow stem cells in patients with cirrhosis: study protocol for a randomised controlled trial: A.King, D.Barton, H.A.Beard, N Than, J.Moore, C.Corbett, J.Thomas, K.Guo, I Guha, D Hollyman, C Yap, R. Fox, S.j.forbes, P.N.Newsome (manuscript ID bmjopen-2015-007700.R1

Liraglutide Efficacy and Action in Non-alcoholic Steatohepatitis (LEAN): Study protocol for a Phase II multi-centre, double-blinded randomised-controlled trialMatthew J. Armstrong, Darren Barton, Piers Gaunt, Diana Hull, Kathy Guo, Deborah Stocken, Stephen CL. Gough, Jeremy W. Tomlinson, Rachel M. Brown, Stefan G. Hübscher, Philip N. Newsome:BMJ Open 2014;3:e003995. Doi:10.1136/bmjopen-2014-003995 

Setting up a patient & public involvement panel to support research in liver disease in a NIHR Biomedical research Unit:  Diana Hull, Darren Barton, Kathy Guo, Christina Russell, Bernadette Aucott, Donna Wiles: British Journal of Nursing:  11/2012